Literature DB >> 8478878

Development of a disease activity score based on judgment in clinical practice by rheumatologists.

D M van der Heijde1, M van 't Hof, P L van Riel, L B van de Putte.   

Abstract

In a prospective study of up to 3 years' duration of 113 patients with early rheumatoid arthritis a disease activity score (DAS) was developed based on the clinical judgment of 6 rheumatologists. The patients were divided in groups with high and low disease activity according to explicit rules. By various statistical methods, including discriminant analysis and multiple regression analysis, a DAS could be defined. This DAS is a continuous measure consisting of the variables Ritchie articular index, number of swollen joints, erythrocyte sedimentation rate and general health measured on a visual analog scale.

Entities:  

Mesh:

Year:  1993        PMID: 8478878

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  200 in total

Review 1.  [Drug therapy of rheumatoid arthritis].

Authors:  U Arndt; M Rittmeister; B Möller
Journal:  Orthopade       Date:  2003-12       Impact factor: 1.087

2.  The challenge of following process, damage, and function in patients with rheumatoid arthritis in clinical care.

Authors:  Josef S Smolen; Daniel Aletaha
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

3.  The development and validation of a screening instrument to identify hospitalized medical patients in need of early functional rehabilitation assessment.

Authors:  Carla Boutin Foster; Delia Gorga; Carolyn Padial; Ann Marie Feretti; Debra Berenson; Robin Kline; Rhonda Belue; Mary E Charlson
Journal:  Qual Life Res       Date:  2004-08       Impact factor: 4.147

4.  Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.

Authors:  T Jonsdottir; J Forslid; A van Vollenhoven; A Harju; S Brannemark; L Klareskog; R F van Vollenhoven
Journal:  Ann Rheum Dis       Date:  2004-04-05       Impact factor: 19.103

5.  Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect.

Authors:  R F van Vollenhoven; S Brannemark; L Klareskog
Journal:  Ann Rheum Dis       Date:  2004-04       Impact factor: 19.103

6.  Patients with rheumatoid arthritis in clinical care.

Authors:  J S Smolen; D Aletaha
Journal:  Ann Rheum Dis       Date:  2004-03       Impact factor: 19.103

Review 7.  The changing face of rheumatoid arthritis: sustained remission for all?

Authors:  John D Isaacs
Journal:  Nat Rev Immunol       Date:  2010-08       Impact factor: 53.106

8.  Treatment and nontreatment predictors of health assessment questionnaire disability progression in rheumatoid arthritis: a longitudinal study of 18,485 patients.

Authors:  Kaleb Michaud; Gene Wallenstein; Frederick Wolfe
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-11-15       Impact factor: 4.794

9.  Monitoring anti-interleukin 6 receptor antibody treatment for rheumatoid arthritis by quantitative magnetic resonance imaging of the hand and power Doppler ultrasonography of the finger.

Authors:  Tamotsu Kamishima; Kazuhide Tanimura; Masato Shimizu; Megumi Matsuhashi; Jun Fukae; Yujiro Kon; Hiromi Hagiwara; Akihiro Narita; Yuko Aoki; Naoki Kosaka; Tatsuya Atsumi; Hiroki Shirato; Satoshi Terae
Journal:  Skeletal Radiol       Date:  2010-11-14       Impact factor: 2.199

10.  Leucocyte complement receptor 1 (CR1/CD35) transcript and its correlation with the clinical disease activity in rheumatoid arthritis patients.

Authors:  D Anand; U Kumar; M Kanjilal; S Kaur; N Das
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.